Jfl Life Sciences share price
NSE: JFLLIFEPharmaceuticals & Biotechnology
Last close ₹10.30down ₹0.50 (4.63%)
Share price at the NSE close on 22 Oct 2026. Previous close ₹10.80.
52-week range of traded prices to 22 Oct 2026
₹8.55Low, 30 Mar 2026₹15.40High, 24 Dec 2025
- Next results date: the board meets on 2 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price.
- ₹34 Cr
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 10 Aug 2026
- 5.0
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 0.7
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 10 Aug 2026
- 15.9%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 10 Aug 2026
- 15.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.47
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 6,000100.0% delivered
Results
Standalone; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 10 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹11 Crdown 82.39%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹1.11 Crdown 32.86%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 10.0%
Revenue by year
Net profit by year, a loss in red
The years either side of a change of basis do not compare. From the year to Mar 2024, the company's revenue for that year, ₹47 Cr, differs from its quarters added, ₹48 Cr.
| ₹ crore | Dec 2024Filed 21 May | Mar 2025Filed 21 May | Jun 2025Filed 11 Aug | Sep 2025Filed 11 Nov | Dec 2025Filed 29 Jan | Mar 2026Filed 29 May | Jun 2026Filed 10 Aug |
|---|---|---|---|---|---|---|---|
| Revenue | 21.3 | 11.7 | 11.6 | 29.9 | 26.8 | 63.1 | 11.1 |
| Net profit | 0.7 | 0.1 | 0.7 | 2.0 | 2.0 | 1.7 | 1.1 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 3.5% | 0.7% | 6.4% | 6.6% | 7.5% | 2.6% | 10.0% |
Standalone. The 7 quarters from Dec 2024, the first on record; the half years before them are below. The latest is shaded.
| ₹ crore | Sep 2024 |
|---|---|
| Revenue | 49.1 |
| Net profit | 3.3 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 6.8% |
Standalone. The half years in the same span that the quarters on record do not fully cover.
Business segments
In the year to Mar 2026 the company reports one business segment, PHARMACEUTICALS, which carries all its revenue.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −51.0% | +54.0% | −68.2% | 0.0% |
| 3 years | −7.8% | – | – | 0.2% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Jfl Life Sciences in market cap. Jfl Life Sciences's own figures are from its last trade, on 22 Oct 2026.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Medicamen OrganicsMEDIORG | 37 | – | – | – | −40.7% | −199.3% | −13.7% | – | 0.00% |
 Vista PharmaceuticalsVISTAPH | 36 | – | 1.0 | – | −60.4% | – | −28.7% | −32.5% | 0.00% |
 Rajnish WellnessRAJNISH | 35 | – | 0.3 | – | +356.9% | – | – | −8.2% | 0.00% |
 Roopa IndustriesROOPAIND | 34 | 269.3 | 2.0 | 7.7 | +3.7% | −93.7% | 0.7% | 15.4% | 0.00% |
 Sandu PharmaceuticalsSANDUPHQ | 33 | 18.5 | 0.8 | 8.8 | +4.2% | +10.3% | 4.1% | 5.3% | 2.94% |
 Medi CapsMEDICAPQ | 31 | – | 0.3 | – | −42.9% | – | −1.5% | −8.7% | 0.00% |
 Chandra Bhagat PharmaCBPL | 29 | 10.4 | 0.9 | – | +34.1% | +229.5% | 9.0% | – | 0.00% |
 Goldline PharmaceuticalGLPL | 29 | 7.0 | 2.0 | – | – | – | 28.9% | – | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up.Highest ₹0.08 a share, year to Mar 2024.
| Ex-date | Type | Per share |
|---|---|---|
| 13 Sep 2024 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹0.25 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
Aug 2026
Jfl Life Sciences share price by year
Each calendar year to 2025.Jfl Life Sciences share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 12.50 | −59.3% | 29.25 | 11.25 |
| 2024 | 30.75 | +122.3% | 35.40 | 12.35 |
| 2023 | 13.83 | +22.1% | 17.83 | 10.83 |
| 2022 | 11.33 | – | 22.17 | 10.67 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2025 is from its first session, 16 Jan 2025. 2022 is from its first session, 8 Sep 2022.
Recent sessions
The last 10 trading days to 22 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 22 Oct 2026 | 10.30 | 10.30 | 10.30 | 10.30 | 10.30 | 6,000 | 100.0% |
| 21 Oct 2026 | 9.85 | 10.80 | 9.85 | 10.80 | 10.32 | 12,000 | 50.0% |
| 19 Oct 2026 | 10.35 | 10.35 | 10.35 | 10.35 | 10.35 | 6,000 | 100.0% |
| 16 Oct 2026 | 11.10 | 11.35 | 10.35 | 10.85 | 10.76 | 36,000 | 50.0% |
| 15 Oct 2026 | 10.75 | 10.85 | 10.75 | 10.85 | 10.80 | 12,000 | 100.0% |
| 14 Oct 2026 | 10.95 | 10.95 | 10.75 | 10.75 | 10.85 | 12,000 | 100.0% |
| 13 Oct 2026 | 10.75 | 10.75 | 10.70 | 10.75 | 10.73 | 18,000 | 100.0% |
| 7 Oct 2026 | 10.20 | 10.25 | 10.20 | 10.25 | 10.22 | 12,000 | 100.0% |
| 6 Oct 2026 | 10.15 | 10.15 | 9.80 | 9.80 | 9.97 | 12,000 | 100.0% |
| 5 Oct 2026 | 10.25 | 10.25 | 10.25 | 10.25 | 10.25 | 12,000 | 100.0% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Bonus share history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 10 Mar 2026 | Rights issue | – | Shareholders were offered new shares. Noted, not adjusted for. |
| 24 Sep 2024 | Bonus | 0.3333 | Holders received 2 bonus shares for every 1 held. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout. Any other event is noted and not adjusted for.
Company details
- Legal name
- Jfl Life Sciences Limited
- NSE symbol
- JFLLIFE
- ISIN
- INE0LA901015
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Sep 2022
- Face value
- ₹10